Company Number: 12532914

Analysis Date: 2025-07-29 17:38 UTC

1. Risk Rating: LOW
   The company demonstrates solid working capital, positive net current assets, and consistently increasing shareholders' funds over recent years. There are no overdue filings or indications of insolvency or regulatory non-compliance.

2. Key Concerns:

• Significant reduction in trade debtors from £24,403 in 2023 to £4,562 in 2024 might indicate changes in revenue recognition or collection practices that warrant further review.
• Taxation and social security creditors remain notable (£7,114 in 2024), which could pose a short-term liquidity concern if not managed proactively.
• The company operates with a very small share capital (£150), which is typical for small private companies but offers limited equity buffer against losses.

3. Positive Indicators:

• Robust liquidity position with cash balances increasing to £141,301 in 2024 from £129,830 in 2023.
• Net current assets improved to £130,468 in 2024 from £106,199 in 2023, indicating healthy working capital management.
• No overdue accounts or confirmation statements, demonstrating good regulatory compliance and governance.
• The company has a stable management team with directors appointed since incorporation and a clear ownership structure.

4. Due Diligence Notes:

• Investigate the cause of the sharp decline in trade debtors and assess the quality and sustainability of revenue streams.
• Review tax and social security creditor management to ensure no build-up of liabilities that could impact cash flow.
• Obtain details on turnover, profitability, and any contingent liabilities not disclosed in the filleted accounts.
• Confirm the nature of the company’s contracts and client base in the specialist medical practice sector to assess operational stability and market position.